Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfasalazine added to standard therapy for acute myeloid leukemia
IRCT20211123053165N2Phase 2Recruiting
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Sulfasalazine plus standard therapy with Placebo plus standard therapy (2 arms). Primary endpoint: Complete remission rate. Started Sep 2026; status: recruiting.
02
Drugs
5-aminosalicylic acid + sulphasalazine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT20211123053165N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211123053165N2.